Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in alzheimer disease

Robert A. Rosenheck, Douglas L. Leslie, Jody L. Sindelar, Edward A. Miller, Peter N. Tariot, Karen S. Dagerman, Sonia M. Davis, Barry D. Lebowitz, Peter Rabins, John K. Hsiao, Jeffery A. Lieberman, Lon S. Schneider

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Context: Second-generation antipsychotics (SGAs) are prescribed for psychosis, aggression, and agitation in Alzheimer disease (AD). Objective: To conduct a cost-benefit analysis of SGAs and placebo (taken to represent a "watchful waiting" treatment strategy) for psychosis and aggression in outpatients with AD. Design: Randomized placebo-controlled trial of alternative SGA initiation strategies. Setting: Forty-two outpatient clinics. Participants: Outpatients with AD and psychosis, aggression, or agitation (N=421). Intervention: Participants were randomly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo with the option of double-blind rerandomization to another antipsychotic or citalopram hydrobromide or open treatment over 9 months. Main Outcome Measures: Monthly interviews documented health service use and costs. The economic perspective addressed total health care and medication costs. Costs of study drugs were estimated from wholesale prices with adjustment for discounts and rebates. Qualityadjusted life-years (QALYs) were assessed with the Health Utilities Index Mark 3 and were supplemented with measures of functioning, activities of daily living, and quality of life. Primary analyses were conducted using all available data. Secondary analyses excluded observations after the first medication change (ie, phase 1 only). Cost-benefit analysis was conducted using the net health benefits approach in a sensitivity analysis in which QALYs were valued at $50 000 per year and $100 000 per year. Results: Average total health costs, including medications, were significantly lower for placebo than for SGAs, by $50 to $100 per month. There were no differences between treatments in QALYs or other measures of function. Phase 1-only analyses were broadly similar. Netbenefit analysis showed greater net health benefits for placebo as compared with other treatments, with probabilities ranging from 50% to 90%. Conclusions: There were no differences in measures of effectiveness between initiation of active treatments or placebo (which represented watchful waiting) but the placebo group had significantly lower health care costs. Trial Registration: clinicaltrials.gov Identifier: NCT00015548.

Original languageEnglish (US)
Pages (from-to)1259-1268
Number of pages10
JournalArchives of General Psychiatry
Volume64
Issue number11
DOIs
StatePublished - Nov 1 2007

Fingerprint

Aggression
Psychotic Disorders
Antipsychotic Agents
Cost-Benefit Analysis
Alzheimer Disease
Placebos
Health Care Costs
Watchful Waiting
Insurance Benefits
olanzapine
Therapeutics
Outpatients
Citalopram
Drug Costs
Risperidone
Activities of Daily Living
Ambulatory Care Facilities
Psychosis
Placebo
Alzheimer's Disease

All Science Journal Classification (ASJC) codes

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Rosenheck, Robert A. ; Leslie, Douglas L. ; Sindelar, Jody L. ; Miller, Edward A. ; Tariot, Peter N. ; Dagerman, Karen S. ; Davis, Sonia M. ; Lebowitz, Barry D. ; Rabins, Peter ; Hsiao, John K. ; Lieberman, Jeffery A. ; Schneider, Lon S. / Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in alzheimer disease. In: Archives of General Psychiatry. 2007 ; Vol. 64, No. 11. pp. 1259-1268.
@article{4c7d53bbb48b4e31803d73d9585baea5,
title = "Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in alzheimer disease",
abstract = "Context: Second-generation antipsychotics (SGAs) are prescribed for psychosis, aggression, and agitation in Alzheimer disease (AD). Objective: To conduct a cost-benefit analysis of SGAs and placebo (taken to represent a {"}watchful waiting{"} treatment strategy) for psychosis and aggression in outpatients with AD. Design: Randomized placebo-controlled trial of alternative SGA initiation strategies. Setting: Forty-two outpatient clinics. Participants: Outpatients with AD and psychosis, aggression, or agitation (N=421). Intervention: Participants were randomly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo with the option of double-blind rerandomization to another antipsychotic or citalopram hydrobromide or open treatment over 9 months. Main Outcome Measures: Monthly interviews documented health service use and costs. The economic perspective addressed total health care and medication costs. Costs of study drugs were estimated from wholesale prices with adjustment for discounts and rebates. Qualityadjusted life-years (QALYs) were assessed with the Health Utilities Index Mark 3 and were supplemented with measures of functioning, activities of daily living, and quality of life. Primary analyses were conducted using all available data. Secondary analyses excluded observations after the first medication change (ie, phase 1 only). Cost-benefit analysis was conducted using the net health benefits approach in a sensitivity analysis in which QALYs were valued at $50 000 per year and $100 000 per year. Results: Average total health costs, including medications, were significantly lower for placebo than for SGAs, by $50 to $100 per month. There were no differences between treatments in QALYs or other measures of function. Phase 1-only analyses were broadly similar. Netbenefit analysis showed greater net health benefits for placebo as compared with other treatments, with probabilities ranging from 50{\%} to 90{\%}. Conclusions: There were no differences in measures of effectiveness between initiation of active treatments or placebo (which represented watchful waiting) but the placebo group had significantly lower health care costs. Trial Registration: clinicaltrials.gov Identifier: NCT00015548.",
author = "Rosenheck, {Robert A.} and Leslie, {Douglas L.} and Sindelar, {Jody L.} and Miller, {Edward A.} and Tariot, {Peter N.} and Dagerman, {Karen S.} and Davis, {Sonia M.} and Lebowitz, {Barry D.} and Peter Rabins and Hsiao, {John K.} and Lieberman, {Jeffery A.} and Schneider, {Lon S.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1001/archpsyc.64.11.1259",
language = "English (US)",
volume = "64",
pages = "1259--1268",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "11",

}

Rosenheck, RA, Leslie, DL, Sindelar, JL, Miller, EA, Tariot, PN, Dagerman, KS, Davis, SM, Lebowitz, BD, Rabins, P, Hsiao, JK, Lieberman, JA & Schneider, LS 2007, 'Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in alzheimer disease', Archives of General Psychiatry, vol. 64, no. 11, pp. 1259-1268. https://doi.org/10.1001/archpsyc.64.11.1259

Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in alzheimer disease. / Rosenheck, Robert A.; Leslie, Douglas L.; Sindelar, Jody L.; Miller, Edward A.; Tariot, Peter N.; Dagerman, Karen S.; Davis, Sonia M.; Lebowitz, Barry D.; Rabins, Peter; Hsiao, John K.; Lieberman, Jeffery A.; Schneider, Lon S.

In: Archives of General Psychiatry, Vol. 64, No. 11, 01.11.2007, p. 1259-1268.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in alzheimer disease

AU - Rosenheck, Robert A.

AU - Leslie, Douglas L.

AU - Sindelar, Jody L.

AU - Miller, Edward A.

AU - Tariot, Peter N.

AU - Dagerman, Karen S.

AU - Davis, Sonia M.

AU - Lebowitz, Barry D.

AU - Rabins, Peter

AU - Hsiao, John K.

AU - Lieberman, Jeffery A.

AU - Schneider, Lon S.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Context: Second-generation antipsychotics (SGAs) are prescribed for psychosis, aggression, and agitation in Alzheimer disease (AD). Objective: To conduct a cost-benefit analysis of SGAs and placebo (taken to represent a "watchful waiting" treatment strategy) for psychosis and aggression in outpatients with AD. Design: Randomized placebo-controlled trial of alternative SGA initiation strategies. Setting: Forty-two outpatient clinics. Participants: Outpatients with AD and psychosis, aggression, or agitation (N=421). Intervention: Participants were randomly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo with the option of double-blind rerandomization to another antipsychotic or citalopram hydrobromide or open treatment over 9 months. Main Outcome Measures: Monthly interviews documented health service use and costs. The economic perspective addressed total health care and medication costs. Costs of study drugs were estimated from wholesale prices with adjustment for discounts and rebates. Qualityadjusted life-years (QALYs) were assessed with the Health Utilities Index Mark 3 and were supplemented with measures of functioning, activities of daily living, and quality of life. Primary analyses were conducted using all available data. Secondary analyses excluded observations after the first medication change (ie, phase 1 only). Cost-benefit analysis was conducted using the net health benefits approach in a sensitivity analysis in which QALYs were valued at $50 000 per year and $100 000 per year. Results: Average total health costs, including medications, were significantly lower for placebo than for SGAs, by $50 to $100 per month. There were no differences between treatments in QALYs or other measures of function. Phase 1-only analyses were broadly similar. Netbenefit analysis showed greater net health benefits for placebo as compared with other treatments, with probabilities ranging from 50% to 90%. Conclusions: There were no differences in measures of effectiveness between initiation of active treatments or placebo (which represented watchful waiting) but the placebo group had significantly lower health care costs. Trial Registration: clinicaltrials.gov Identifier: NCT00015548.

AB - Context: Second-generation antipsychotics (SGAs) are prescribed for psychosis, aggression, and agitation in Alzheimer disease (AD). Objective: To conduct a cost-benefit analysis of SGAs and placebo (taken to represent a "watchful waiting" treatment strategy) for psychosis and aggression in outpatients with AD. Design: Randomized placebo-controlled trial of alternative SGA initiation strategies. Setting: Forty-two outpatient clinics. Participants: Outpatients with AD and psychosis, aggression, or agitation (N=421). Intervention: Participants were randomly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo with the option of double-blind rerandomization to another antipsychotic or citalopram hydrobromide or open treatment over 9 months. Main Outcome Measures: Monthly interviews documented health service use and costs. The economic perspective addressed total health care and medication costs. Costs of study drugs were estimated from wholesale prices with adjustment for discounts and rebates. Qualityadjusted life-years (QALYs) were assessed with the Health Utilities Index Mark 3 and were supplemented with measures of functioning, activities of daily living, and quality of life. Primary analyses were conducted using all available data. Secondary analyses excluded observations after the first medication change (ie, phase 1 only). Cost-benefit analysis was conducted using the net health benefits approach in a sensitivity analysis in which QALYs were valued at $50 000 per year and $100 000 per year. Results: Average total health costs, including medications, were significantly lower for placebo than for SGAs, by $50 to $100 per month. There were no differences between treatments in QALYs or other measures of function. Phase 1-only analyses were broadly similar. Netbenefit analysis showed greater net health benefits for placebo as compared with other treatments, with probabilities ranging from 50% to 90%. Conclusions: There were no differences in measures of effectiveness between initiation of active treatments or placebo (which represented watchful waiting) but the placebo group had significantly lower health care costs. Trial Registration: clinicaltrials.gov Identifier: NCT00015548.

UR - http://www.scopus.com/inward/record.url?scp=35948979240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948979240&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.64.11.1259

DO - 10.1001/archpsyc.64.11.1259

M3 - Article

C2 - 17984395

AN - SCOPUS:35948979240

VL - 64

SP - 1259

EP - 1268

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 11

ER -